International team discovers unique pathway for treating deadly children's brain cancer
An international team of researchers has discovered a new pathway that may improve success against an incurable type of children's brain cancer. The study results suggest that scientists have identified a unique way to disrupt the cellular process that contributes to Diffuse Intrinsic Pontine Gliomas (DIPG).
Journal Ranked Second in Radiology, Nuclear Medicine and Medical Imaging
Medical Image Analysis, co-founded in 1996 by James Duncan, PhD, the Ebenezer K. Hunt Professor of Biomedical Engineering and Radiology & Biomedical Imaging, is the second-ranked journal in radiology, nuclear medicine and medical imaging, with an Impact Factor of 8.8, according to the Journal Citation Report.
Jason Cai, PhD, Awarded NIH Grant for PET Ligand Development
Zhengxin (Jason) Cai, PhD, Assistant Professor, Yale University PET Center, has been awarded an Exploratory/Development R21 grant from the National Institutes of Health (NIH). Dr. Cai’s research project titled, "Development of BBB Permeable PD-L1 PET Imaging Agents,” will involve synthesis and radiolabeling a library of small molecule PD-L1 ligands as potential PET imaging probes, aiming to find one probe that could penetrate the blood-brain barrier (BBB) and allow for the quantification of PD-L1 in brain tumor or metastasis.
New insight into a struggling AstraZeneca anti-VEGF drug could expand its use in cancer
AstraZeneca’s experimental cancer drug cediranib was originally developed to inhibit VEGF, a protein that prompts the growth of the blood vessels tumors need to survive. But in clinical trials it hasn’t proven to be all that effective, failing to stack up to Roche’s anti-VEGF blockbuster Avastin.
Yale Study Identifies How Cancer Drug Inhibits DNA Repair in Cancer Cells
Yale Cancer Center researchers have found that a cancer drug thought to be of limited use possesses an unforeseen property. It is able to stop certain cancer cells from repairing their DNA in order to survive. The study suggests that combining this drug, cediranib, with other agents could potentially deliver a lethal blow in cancer that uses a specific process to create DNA repair cells.
Morris to Explore Ethics of Neuroimaging
Evan Morris, PhD, has been accepted as a visiting scholar at The Hasting Center in Garrison, N.Y. for two weeks in August. Morris plans to write a draft of a research paper exploring the ethics of neuroimaging. A professor of Radiology & Biomedical Imaging, Biomedical Engineering and Psychiatry, his research for the last 25 years has been in the imaging of drug addiction and alcoholism. Most of his work has been with PET imaging, although some has been with fMRI.
Knowing the Risks: The Genetics of Breast and Ovarian Cancer
Dr. Ryan Jensen’s work, spurred by a pair of WHRY grants, continues progress toward models uncovering how genetic mutations lead to cancer and helping guide patients and doctors toward decisions that can produce the best health outcomes.
PET Imaging of Beta Cell Mass Featured in Journal of Nuclear Medicine
Type 1 diabetes mellitus (T1DM) is characterized by a loss of β-cells in the islets of Langerhans of the pancreas and subsequent deficient insulin secretion in response to hyperglycemia. Development of an in vivo test to measure β-cell mass (BCM) would greatly enhance the ability to track diabetes therapies.
Yale Cancer Researchers Suggest New Treatment for Rare Inherited Cancer
Studying two rare inherited cancer syndromes, Yale Cancer Center (YCC) scientists have found the cancers are driven by a breakdown in how cells repair their DNA. The discovery, published today in Nature Genetics, suggests a promising strategy for treatment with drugs recently approved for other forms of cancer.